Explore · Entity Annotation Prototype (beta)

Filter articles

Entity familyJournalContent resourceEvidence policyAutomated confidence floorArticles per pageReset filters

“Reviewed + threshold” includes every confirmed correction plus unreviewed proposals at or above the selected model score.

Matching articles

29,499 articles · page 34 of 2459

Factors associated with generalised anxiety disorder and depression among adults living with diabetes and hypertension comorbidity in rural Bangladesh: findings from a cross-sectional study

bmjopen · abstract · 2025-09-05 · 32 matching annotations

99.0%

Patient Health Questionnaire-9 diabetes hypertension GAD depression

…ere considered as having GAD and individuals scoring ≥10 on the Patient Health Questionnaire-9 scale were considered as having depression. The outcome variabl…

OP76 Do the harmful effects of obesity differ by socio-economic position? Assessing effect modification using linked UK biobank cohort data

jech · abstract · 2025-08-24 · 32 matching annotations

98.9%

diabetes Obesity sleep apnoea essential hypertension osteoarthritis pancreatitis gout

… by the main effects of obesity and low SEP (TDI tertile) were: diabetes 3.03 (2.66; 3.4), essential hypertension 0.51 (0.43; 0.58), gou…

OC83 A 5 year single centre clinical practice review of the safety and efficacy of ustekinumab treatment 2019–2024 for children with refractory IBD

flgastro · abstract · 2025-08-20 · 32 matching annotations

99.5%

Ustekinumab IBD Adalimumab ulcerative colitis

…29 children had significant IBD clinical symptoms when starting Ustekinumab. 16/20 (80%) saw some improvements at 3 months. At 6 months 8/2…

Influence of metabolism-related comorbidities and insulin resistance on new onset of chronic kidney disease in a health check-up population: a two-stage retrospective cohort study

bmjdrc · abstract · 2025-07-27 · 32 matching annotations

93.9%

Chinese People’s Liberation Army General Hospital CKD

…al analyses) used data from health check-up participants at the Chinese People’s Liberation Army General Hospital (2009–2021). The cross-sectional analysis included 83 346 parti…

Phase III LUNA clinical programme: design of four randomised, double-blind, placebo-controlled studies assessing the efficacy and safety of tozorakimab in patients with symptomatic COPD and a high risk of exacerbations

bmjresp · abstract · 2026-07-20 · 31 matching annotations

98.5%

tozorakimab chronic obstructive pulmonary disease TITANIA COPD OBERON MIRANDA

…nts recruited from the placebo arm will be re-randomised 1:1 to tozorakimab or placebo. The primary endpoint in OBERON, TITANIA and MIRANDA…

E-071 Tenzingplasty reduces the need for balloon angioplasty prior to stent placement for intracranial atherosclerotic disease

neurintsurg · abstract · 2026-07-19 · 31 matching annotations

96.1%

Tenzing intracranial atherosclerotic disease Tenzingplasty Route 92 Medical intracranial atherosclerotic disease (ICAD)ICAD

…er diameter of 1.2mm (Tenzing 5), 1.6mm (Tenzing 7), and 2.1mm (Tenzing 8). These Tenzing OD approximate commonly used balloon microcat…

OC84 Substantial cost benefit of switching from intravenous to subcutaneous infliximab in adolescent inflammatory bowel disease

flgastro · abstract · 2026-06-29 · 31 matching annotations

93.2%

Crohn’s disease National Institute for Health and Care Excellence inflammatory bowel disease SC-IFX IBD infliximab

…(infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis. https://www.nice.org.uk/advice/es35/cha…

O42 Comparative effectiveness and gastrointestinal safety of orlistat versus liraglutide in obesity and type 2 diabetes adults: a real-world cohort study

gutjnl · abstract · 2026-06-23 · 31 matching annotations

99.2%

Orlistat liraglutide obesity cholelithiasis

…and upper gastrointestinal cancers were similar between groups. Orlistat was associated with a higher risk of kidney stones (5.9% vs 4.5…

O51 Long-term elafibranor in primary sclerosing cholangitis (PSC): interim safety and efficacy data from the ELMWOOD open-label extension (OLE) trial

gutjnl · abstract · 2026-06-23 · 31 matching annotations

99.0%

Numeric Rating Scale ELA PSC elafibranor COVID-19

…DBP baseline in liver biochemistry and pruritus (per Worst-Itch Numeric Rating Scale [WI NRS]) to OLE Week (W)28, and in non-invasive tests (NITs) o…

291 Primary prevention in multimorbid patients: rethinking the classification of primary prevention and the role of bempedoic acid in achieving NICE targets in rural primary care

heartjnl · abstract · 2026-06-09 · 31 matching annotations

99.4%

bempedoic acid bempedoic acid-containing ASCVD ezetimibe atherosclerotic cardiovascular disease diabetes hypertension NICE

…ntion populations.2 This analysis assesses the effectiveness of bempedoic acid, a non-statin lipid-lowering therapy, in achieving NICE non-HDL…

Non-arteritic anterior ischaemic optic neuropathy incidence in placebo-controlled clinical trials of liraglutide or semaglutide

bjophthalmol · abstract · 2026-04-28 · 31 matching annotations

98.3%

semaglutide type 2 diabetes liraglutide non-arteritic anterior ischaemic optic neuropathy NAION

…ufactured GLP-1RA products (active ingredients: liraglutide and semaglutide) in people with type 2 diabetes and/or overweight/obesity. Pote…

GLP-1 receptor agonists and risk of all cause and cause specific acute pancreatitis: target trial emulation

bmjmed · abstract · 2026-04-22 · 31 matching annotations

97.5%

type 2 diabetes acute pancreatitis GLP-1RA GLP-1RAs

…ts 333 687 users of the Veterans Affairs healthcare system with type 2 diabetes initiating GLP-1RA (n=132 551) or sulfonylureas (n=201 136) bet…

Follow the entities shaping the evidence.

Browse by entity family

Popular entities in these results